Recent studies have revealed that overexpression of multidrug resistance (mdr) gene in some human neoplasms is correlated with poor prognostic responses of these tumors to chemotherapeutic agents. Elucidating the molecular basis of mdr gene expression in normal and in malignant cells may provide important insights into clinical applications of chemotherapy of these tumors. We propose here to investigate the regulation of mouse mdr gene expression in hepatoma-derived cells and in uterine epithelial (UE) cells of pregnant animals. In both cases, mdrl gene is activated. Preliminary results demonstrated that mdrl gene expression can be activated by steroid hormone in hepatoma cells. It is our aim to determine whether the activation mechanism is at the transcriptional or at the posttranscriptional levels and to elucidate the possible hormone responsible DNA elements in the mdrl locus. Furthermore, a 33-bp sequence located in the promoter region of mdrl gene is involved with mdrl expression in hepatoma cells. We propose experiments to further characterize this cis-acting DNA element. Possible trans-activating factor(s) interacting with this DNA element will be purified and genes encoding these factors will be cloned. The activation mechanism of mdrl gene in UE cells during pregnancy will be studied using primary culture derived from UE. This primary culture maintains its apparent in vivo characteristics. The role of steroid hormones in this activation mechanism will be studied; and possible cis-acting DNA sequences in the mdr gene will be determined by transient transfection using microinjection method. These proposed studies may help us to learn the mechanisms of mdr gene regulation in normal and malignant cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA055813-03
Application #
2096919
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1992-02-07
Project End
1996-01-31
Budget Start
1994-02-01
Budget End
1995-01-31
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Pathology
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Peterson, Erich A; Bauer, Michael A; Chavan, Shweta S et al. (2015) Enhancing cancer clonality analysis with integrative genomics. BMC Bioinformatics 16 Suppl 13:S7
Khan, R; Apewokin, S; Grazziutti, M et al. (2015) Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma. Leukemia 29:1195-201
Barlogie, Bart; Mitchell, Alan; van Rhee, Frits et al. (2014) Curing myeloma at last: defining criteria and providing the evidence. Blood 124:3043-51
Papanikolaou, Xenofon; Johnson, Sarah; Garg, Tarun et al. (2014) Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis. Oncotarget 5:4118-28
van Rhee, Frits; Giralt, Sergio; Barlogie, Bart (2014) The future of autologous stem cell transplantation in myeloma. Blood 124:328-33
Bauer, Michael A; Chavan, Shweta S; Peterson, Erich A et al. (2014) Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing. BMC Bioinformatics 15 Suppl 11:S3
Peterson, Erich A; Chavan, Shweta S; Bauer, Michael A et al. (2014) Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis. BMC Bioinformatics 15 Suppl 11:S9
Chavan, Shweta S; Bauer, Michael A; Peterson, Erich A et al. (2013) Towards the integration, annotation and association of historical microarray experiments with RNA-seq. BMC Bioinformatics 14 Suppl 14:S4
Usmani, S Z; Crowley, J; Hoering, A et al. (2013) Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia 27:226-32
Usmani, Saad Z; Sawyer, Jeffrey; Rosenthal, Adam et al. (2013) Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood 121:4753-7

Showing the most recent 10 out of 28 publications